Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4323993 | 0.81 | — | — | |
| SCHEMBL29659643 | 0.81 | — | — | |
| SCHEMBL30046498 | 0.80 | CCNK (0.33) | EGFR | |
| SCHEMBL29265688 | 0.79 | L3MBTL1 (0.42) | — | |
| SCHEMBL16653865 | 0.79 | L3MBTL1 (0.42) | — | |
| SCHEMBL14855193 | 0.77 | L3MBTL1 (0.45) | — | |
| SCHEMBL13245020 | 0.77 | L3MBTL1 (0.45) | — | |
| SCHEMBL29659499 | 0.76 | SMN1; SMN2 (0.35) | EGFR | |
| Water SCHEMBL30521987 | 0.76 | L3MBTL1 (0.44) | — | |
| SCHEMBL20235765 | 0.74 | EGFR (0.36) | EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240277722-A1 | CANCER THERAPY USING A COMBINATION OF CDK7 INHIBITOR WITH AN ANTI-CANCER AGENT | AURIGENE ONCOLOGY LTD (IN) | 2024-08-22 | — | — | US | claimed |
| US-20240016811-A1 | CANCER THERAPY USING A COMBINATION OF CDK7 INHIBITOR WITH AN ANTI-MICROTUBULE AGENT | AURIGENE ONCOLOGY LIMITED (IN) | 2024-01-18 | — | — | US | claimed |
| US-12331023-B2 | Substituted heterocyclyl derivatives as CDK inhibitors | AURIGENE ONCOLOGY LIMITED (IN) | 2025-06-17 | — | — | US | disclosed |
| US-20240277722-A1 | CANCER THERAPY USING A COMBINATION OF CDK7 INHIBITOR WITH AN ANTI-CANCER AGENT | AURIGENE ONCOLOGY LTD (IN) | 2024-08-22 | — | — | US | disclosed |
| US-20230250062-A9 | Substituted Heterocyclyl Derivatives as CDK Inhibitors | AURIGENE ONCOLOGY LIMITED (IN) | 2023-08-10 | — | — | US | disclosed |
| US-20220098156-A1 | Substituted Heterocyclyl Derivatives as CDK Inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2022-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250062-A9 | Substituted Heterocyclyl Derivatives as CDK Inhibitors | CDK19, CDK9, CDK1 | EGFR 2065/4885 |
| US-20240277722-A1 | CANCER THERAPY USING A COMBINATION OF CDK7 INHIBITOR WITH AN ANTI-CANCER AGENT | CDK7, CDK17, CDK6 | EGFR 1287/4885 |
| US-20240016811-A1 | CANCER THERAPY USING A COMBINATION OF CDK7 INHIBITOR WITH AN ANTI-MICROTUBULE AGENT | CDK7, CDK17, HDAC7 | EGFR 2251/4885 |
| US-12331023-B2 | Substituted heterocyclyl derivatives as CDK inhibitors | CDK19, CDK9, CDK1 | EGFR 2065/4885 |
| US-20220098156-A1 | Substituted Heterocyclyl Derivatives as CDK Inhibitors | CDK19, CDK9, CDK1 | EGFR 2065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.